Federal preemption is a key defense in drug and medical device product liability cases, and the FDA’s regulatory framework is the ever-present background factor for our clients and for litigation involving their products. This webinar will provide a brief introduction to federal preemption, aimed at newer lawyers, before shifting to a robust discussion of strategically raising preemption defenses, and will conclude with a forecast of where federal preemption is headed, particularly given the impending changes to the FDA’s 510(k) clearance program.
Who Should Attend
What You Will Learn
Taryn W. Harper is an associate at Greenberg Traurig LLP in Atlanta, Georgia, focusing her practice on products liability litigation, with an emphasis on pharmaceutical and medical device litigation. She has experience with products liability matters in both state and federal courts, including single plaintiff actions and mass tort actions involving a variety of products and medical issues. Taryn is co-editor of Raising the Bar, the newsletter of the DRI Young Lawyers Committee.
Erica A. Holzer is an associate at Maslon LLP in Minneapolis, Minnesota, representing clients in complex commercial disputes primarily in the areas of tort and product liability, consumer fraud, business torts, and breach of contract actions.
Allison Ng is an is an associate at Greenberg Traurig LLP in Atlanta, Georgia, focusing her practice on commercial litigation and products liability litigation with an emphasis on pharmaceutical, medical devices, and other consumer products. She has experience litigating complex issues in state and federal courts involving mass torts, failure to warn, breach of warranties, trade secrets misappropriation, unfair trade practices, and insurer tortious bad faith.
Tom R. Pack is an associate at Maslon LLP in Minneapolis, Minnesota, where he represents businesses in product liability matters and in other complex business litigation, with a focus on the drug and medical device industries. Tom is co-vice-chair of the Young Lawyers Diversity Subcommittee.
DRI, The Voice of the Defense Bar, intends to comply with all applicable anti trust laws. Accordingly, DRI cannot, and will not, tolerate conduct that could lead to, or even suggest, agreement among its members that might restrain trade or violate such laws. All such conduct is a violation of DRI policy